Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER “De-Layering” In Second Half 2003, Following Incorporation Of CBER

Executive Summary

FDA's Center for Drug Evaluation & Research will undergo a "de-layering" in mid- to late 2003 as part of FDA's overall review of management functions
Advertisement

Related Content

McClellan’s Policy Clout Creates Big Shoes To Fill At FDA
McClellan’s Policy Clout Creates Big Shoes To Fill At FDA
FDA Commissioner’s Office To Be Re-aligned Further Under Booz Allen Plan
FDA Commissioner’s Office To Be Re-aligned Further Under Booz Allen Plan
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
FDA Crisis Management Office To Streamline Counterterrorism Response
Advertisement
UsernamePublicRestriction

Register

PS040721

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel